Expert Interview
A third look at FDA approved BIMZELX® (bimekizumab) for moderate to severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy.
Ticker(s): UCBInstitution: Omni Dermatology
- Practices general, cosmetic, and surgical dermatology, including MOHS surgery.
- treats 5 - 20 patients per week for psoriasis
- Excited about Bimzelx and familiar with P3 results
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
